3 przypadki pacjentów, u których warto stosować ramipryl Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2018
Słowa kluczowe:
ramipryl, ACE-inhibitory, nadciśnienie tętnicze
##plugins.themes.bootstrap3.article.main##
Abstrakt
Praca przedstawia charakterystykę 3 pacjentów z rozpoznaniem nadciśnienia tętniczego z towarzyszącymi czynnikami ryzyka sercowo-naczyniowego. Szczegółowo omówiono grupy chorych, u których ACE-inhibitory są optymalnym lekiem zarówno w monoterapii, jak i w terapii skojarzonej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dąbrowska, D., & Mamcarz , A. (2018). 3 przypadki pacjentów, u których warto stosować ramipryl . Medycyna Faktów , 11(1(38), 45-48. https://doi.org/10.24292/01.MF.0118.7
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. United States Patent Nr 5,061,722.
2. AIRE trial investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-828.
3. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. The Lancet 1999; 354: 359-364.
4. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO- HOPE substudy Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
5. FDA. Altace (Ramipril) Capsules.
6. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
7. Bosch J., Lonn E., Pogue J. et al.; HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
8. Bosch J., Yusuf S., Pogue J. et al.; on behalf of the HOPE Investigators: Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2002; 324: 1-5.
9. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
10. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok: wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś. Tętn. Prakt. 2015; 1: 1-70.
11. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
12. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
13. Ruggenenti P., Perna A., Gherardi G. et al.: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252-1256.
14. Mann J.F., Schmieder R.E., McQueen M. et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547-553.
15. Fox K.M.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double- blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9287): 1033-1041.
2. AIRE trial investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-828.
3. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. The Lancet 1999; 354: 359-364.
4. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO- HOPE substudy Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
5. FDA. Altace (Ramipril) Capsules.
6. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
7. Bosch J., Lonn E., Pogue J. et al.; HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
8. Bosch J., Yusuf S., Pogue J. et al.; on behalf of the HOPE Investigators: Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2002; 324: 1-5.
9. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
10. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok: wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś. Tętn. Prakt. 2015; 1: 1-70.
11. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
12. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
13. Ruggenenti P., Perna A., Gherardi G. et al.: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252-1256.
14. Mann J.F., Schmieder R.E., McQueen M. et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547-553.
15. Fox K.M.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double- blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9287): 1033-1041.